1910, the only AI-native biotech pioneering small and large molecule therapeutics discovery, today announced the publication of PEGASUS™, a multimodal AI model that achieves state-of-the-art accuracy ...
1910 is on a mission to “make undruggable targets a thing of the past” by “turning every pharma company into an AI company,” says founder and CEO, Jen Asher, PhD. The Sam Altman–backed AI drug ...
PEGASUS™ is an industry-first in peptide design: It achieves AI-driven generative design of the first permeable macrocyclic peptide with more than two polar or ionizable fragments. Surrogate assays ...
The MarketWatch News Department was not involved in the creation of this content. -- PEGASUS(TM) is an industry-first in peptide design: It achieves AI-driven generative design of the first permeable ...
The MarketWatch News Department was not involved in the creation of this content. -- PEGASUS(TM) is an industry-first in peptide design: It achieves AI-driven generative design of the first permeable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results